{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T20:25:48Z","timestamp":1780604748333,"version":"3.54.1"},"reference-count":0,"publisher":"Esmon Publicidad, SA","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Investig Allergol Clin"],"published-print":{"date-parts":[[2023,7,26]]},"abstract":"<jats:p>Background and objectives: Bilastine is a nonsedating second-generation antihistamine for the symptomatic treatment of allergic rhinoconjunctivitis and urticaria. Our study aimed to evaluate the optimal dose, efficacy, and safety of a newly developed once-daily preservative-free ophthalmic formulation of bilastine for allergic conjunctivitis. Methods: Our phase 2, single-center, double-masked, randomized trial compared the efficacy of 3 doses of a bilastine ophthalmic formulation (0.2%, 0.4%, and 0.6%) with that of vehicle for the treatment of allergic conjunctivitis. The primary efficacy endpoint was the reduction in ocular itching. The Ora-CAC Conjunctival Allergen Challenge model was used to assess ocular and nasal symptoms at the onset of action (15 minutes) and at 8- and 16-hours after treatment. Tolerance and safety were also evaluated. Results: A total of 121 adults with seasonal and\/or perennial ocular allergy were randomized. Bilastine ophthalmic formulations 0.2%, 0.4%, and 0.6% were significantly superior (P&gt;.001) to vehicle for the treatment of ocular itching at 3, 5, and 7 minutes after challenge at onset of action (15 minutes) and at 8 hours after treatment. Bilastine 0.6% was also effective at 16 hours after treatment. Treatment differences for bilastine 0.6% were statistically significant (P&lt;.001) compared to vehicle at all timepoints for tearing, eyelid swelling, and nasal symptoms. No relevant adverse events were observed. Conclusions: All the tested ophthalmic bilastine doses were efficacious for rapid reduction of ocular itching. The 0.6% formulation was effective up to 16 hours after treatment, making it suitable for once-daily administration. The new formulation was safe and well tolerated.<\/jats:p>","DOI":"10.18176\/jiaci.0800","type":"journal-article","created":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T15:02:23Z","timestamp":1646146943000},"page":"271-280","source":"Crossref","is-referenced-by-count":9,"title":["Efficacy of Once-Daily Ophthalmic Bilastine for the Treatment of Allergic Conjunctivitis: A Dose-Finding Study"],"prefix":"10.18176","volume":"33","author":[{"given":"PJ","family":"Gomes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JB","family":"Ciolino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P","family":"Arranz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G","family":"Hern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N","family":"Fern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"7491","published-online":{"date-parts":[[2023,7,27]]},"container-title":["Journal of Investigational Allergy and Clinical Immunology"],"original-title":["English"],"deposited":{"date-parts":[[2023,7,27]],"date-time":"2023-07-27T11:41:47Z","timestamp":1690458107000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jiaci.org\/summary\/vol33-issue4-num2722"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,26]]},"references-count":0,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2023,7,27]]},"published-print":{"date-parts":[[2023,7,26]]}},"URL":"https:\/\/doi.org\/10.18176\/jiaci.0800","relation":{},"ISSN":["1018-9068"],"issn-type":[{"value":"1018-9068","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7,26]]}}}